Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Dasatinib in CML
NCT02011945Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of nivolumab in chronic myeloid leukemia (CML) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Dose Limiting Toxicities, Incidence of Adverse Events and 2 more. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02011945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011945.